Consensus estimates for Grifols SA anticipate Q2 2026 revenue of $2.07 billion and an EPS of $0.27, while the stock currently trades at $10.45 compared to an average analyst price target of $14.20.
Investors are primarily focused on the company's ability to generate positive free cash flow and successfully execute its deleveraging strategy to reduce its net debt-to-EBITDA ratio.
Performance has recently been supported by robust plasma collection volumes and the completion of the Shanghai RAAS stake sale, which has improved the company's immediate liquidity profile. Analysts will be closely monitoring whether margin improvements in the core Biopharma segment can offset high interest expenses and restore market confidence in corporate governance.